Skip to content

Biomarkers in Islet Cell Transplantation for Type 1 Diabetes

Research output: Contribution to journalReview article

Original languageEnglish
Article number94
JournalCurrent diabetes reports
Issue number10
Early online date5 Sep 2018
DateAccepted/In press - 4 Sep 2018
DateE-pub ahead of print - 5 Sep 2018
DatePublished (current) - 1 Oct 2018


Purpose of Review: Islet transplantation, an important approach to achieve insulin independence for individuals with type 1 diabetes, is limited by the lack of accurate biomarkers to track beta-cell death post islet infusion. In this review, we will discuss existing and recently described biomarkers.

Recent Findings: As beta cells are killed by the immune system, fragments of beta cell-specific cell-free DNA and proteins are released into the periphery. Several different strategies to identify these fragments have been described. Some circulating, non-coding microRNAs, particularly miRNA-375 are also showing potential to reflect the rate of beta cell loss post-clinical islet transplantation.

Summary: Recent advances in identifying accurate beta cell-specific biomarkers such as differentially methylated insulin cell-free DNA and circulating miRNA-375 may help predict clinical outcomes. More studies are required to examine the robustness of these biomarkers to detect chronic beta-cell loss in islet transplantation recipients.

    Research areas

  • Biomarker, Cell-free DNA, Islet transplantation, microRNA 375, Type 1 diabetes

Download statistics

No data available



  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via Springer at Please refer to any applicable terms of use of the publisher.

    Final published version, 656 KB, PDF document

    Licence: CC BY


View research connections

Related faculties, schools or groups